Mazen Noureddin
Houston Methodist Hospital
Appearances
DateMay 7, 2023SOCIETY: DDWPresenters
Houston Methodist HospitalIndiana University School of Medicine- DateMay 6, 2023SOCIETY: AASLD
Presenter
Houston Methodist Hospital - DateMay 21, 2024
Presenter
Houston Methodist Hospital - DateMay 19, 2024INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…
Presenter
University of California San DiegoSpeakers
Houston Methodist Hospital - DateMay 20, 2024
Presenter
Houston Methodist Hospital - DateMay 21, 2024
Presenter
Houston Methodist Hospital - DateMay 21, 2024BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
Presenter
Speakers
DateMay 4, 2025SOCIETY: DDWModerators
Houston Methodist HospitalRichmond VA Medical Center
